Association for Molecular Pathology vs Myriad Genetics: The Case That Changed DNA
Association for Molecular Pathology vs Myriad Genetics: The Case That Changed DNA
This case shapes current gene ownership debates. Legal rulings on gene patents influence testing access and innovation.
Association for Molecular Pathology vs Myriad Genetics: The Case That Changed DNA is a Supreme Court ruling on human DNA patents. This decision states naturally occurring DNA is not patentable. Synthetic cDNA can be patented. Studies indicate this ruling increased genetic testing competition.
How gene patent rules drive commercial research. Patent eligibility determines who can develop and price tests. Fair access to genetic information supports broader research. Research shows clear property rules encourage responsible innovation.
A single gene patent ruling reshaped molecular diagnostics. Removing gene monopolies expanded testing options for patients.
Q: What does cDNA mean in this context? A: Complementary DNA made in the lab; it can be patented.
Q: Why does this case still matter? A: It defines modern boundaries for genetic testing and research.
